News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research> JPM Raises MicroPort MedBot-B (02252.HK) TP to HKD42, Rating Overweight
JPMorgan issued a research report stating that MicroPort MedBot-B (02252.HK)'s FY2026 guidance marks a clear shift from "commercialization validation" to "earnings release", with m...
Reset
Send
The window will close in 5 seconds
<Research> JPM Raises MicroPort MedBot-B (02252.HK) TP to HKD42, Rating Overweight
Close
Recommend
11
Positive
12
Negative
5
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

JPMorgan issued a research report stating that MicroPort MedBot-B (02252.HK)  -0.640 (-2.246%)    Short selling $3.80M; Ratio 3.182%   's FY2026 guidance marks a clear shift from "commercialization validation" to "earnings release", with management setting out clear revenue, profitability and cash flow targets. The company expects revenue of approximately RMB1.1 billion this year, nearly doubling YoY, while achieving a turnaround from net breakeven to profitability and generating positive free cash flow, indicating entry into an operating leverage phase.

The bank noted that as of early April, the company had installed 23 Toumai surgical robots and held 86 units in backlog orders. Management guided for about 103 to 113 installations in 1H26 and at least 200 units for the full year, adding that delivery bottlenecks seen in 2H25 have been resolved. Overseas markets will continue to serve as the core growth engine, with demand spanning Europe, Asia (excluding China) and Latin America.

Related News BofAS Cuts MicroPort (00853.HK) TP to HKD13.9, Reiterates Buy
JPM raised its gross margin assumptions for MicroPort MedBot by 5 to 6 ppts for 2026 to 2028, while maintaining its 2026 revenue forecast at RMB1.4 billion, above market consensus. The bank lifted its TP to HKD42 from HKD41 and maintained an Overweight rating, naming the company as its top pick in the MedTech sector.

Separately, JPM reiterated Overweight ratings on Mindray Medical (300760.SZ)  -0.240 (-0.152%)   and MicroPort Scientific (00853.HK)  -0.180 (-2.011%)    Short selling $9.66M; Ratio 4.620%   ; assigned a Neutral rating to Shanghai MicroPort Endovascular MedTech (688016.SH)  -2.400 (-2.342%)   ; and gave an Underweight rating to MicroPort EP MedTech (688351.SH)  -0.550 (-2.304%)   . The bank said MicroPort Scientific has diversified platform exposure and expects part of this year's net profit to be supported by non-recurring items, even as MicroPort MedBot's revenue growth accelerates. It added that MicroPort Scientific's fundamentals are improving, with earnings quality expected to gradually enhance. JPM trimmed its TP on MicroPort Scientific to HKD18 from HKD18.2. (ec/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-13 16:25.) (A Shares quote is delayed for at least 15 mins.)



Related News UBS Upgrades MICROPORT MEDBOT (02252.HK) to Buy on Strong Overseas Sales, Expects Breakeven in 1H26
This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.